RT info:eu-repo/semantics/article
T1 Clinical perspective and translational oncology of liquid biopsy
A1 Fernández Lázaro, Diego
A1 García Hernández, Juan Luis
A1 Caballero García, Alberto
A1 Caballero del Castillo, Aurora
A1 Villaverde Hueso, María
A1 Cruz Hernández, Juan Jesús
K1 Cancer research
K1 Cancer - Early detection
K1 Cancer - Molecular aspects
K1 Liquid Biopsy
K1 General practice (Medicine)
K1 Translational Medical Research
K1 3207.13 Oncología
AB The term liquid biopsy (LB) refers to the study of circulating tumor cells, circulating tumors nucleic acids free of cells or contained in exosomes, and information about platelets associated with tumors. LB can be performed in different biofluids and allows the limitations of tissue biopsy to be overcome offering possibilities of tumor identification reflecting in real time tumor heterogeneity. In addition, LB allows screening and early detection of cancer, real-time monitoring of therapy, stratification and therapeutic intervention, a therapeutic target and resistance mechanism, and a risk of metastatic relapse. Currently, LB has been shown to be effective for its application in different types of tumors including lung, colorectal, prostate, melanoma, breast and pancreatic cancer, by the determination and identification of biomarkers that with a high probability have the potential to change the way in which medical oncology could predict the course of the disease. These biomarkers make it possible to capture the heterogeneity of the cancer, monitor its clonal evolution, indicate new treatments or retreatments and evaluate the responses to different evolutionary and/or therapeutic pressures in the cancer disease.
PB MDPI
SN 2075-4418
YR 2020
FD 2020
LK https://uvadoc.uva.es/handle/10324/57763
UL https://uvadoc.uva.es/handle/10324/57763
LA eng
NO Diagnostics,  2020, Vol. 10, Nº. 7, 443
NO Producción Científica
DS UVaDOC
RD 24-nov-2024